PROBLEM TO BE SOLVED: To provide an anti-fibrotic agent for treating and preventing idiopathic pulmonary fibrosis by inhibiting nuclear translocation of phosphorylated Smad.SOLUTION: According to the present invention, there is provided an anti-fibrotic agent comprising as an active ingredient one or both of a glucosylceramide synthase inhibitor and a lactosylceramide synthase inhibitor.EFFECT: The anti-fibrotic agent can be used for suppressing the expression process of protein related to tissue fibrosis to treat and prevent fibrosis in various tissues, such as the lungs, kidneys, liver, heart, skin, bone marrow, pancreas, and eyes, in particular treat and prevent idiopathic pulmonary fibrosis.SELECTED DRAWING: Figure 1COPYRIGHT: (C)2018,JPO&INPIT【課題】リン酸化Smadの核内移行を阻害することによる、特発性肺線維症を治療、予防する抗線維症剤の提供。【解決手段】グルコシルセラミド合成酵素阻害剤、ラクトシルセラミド合成酵素阻害剤のいずれか、または両方を有効成分とする抗線維症剤。【効果】組織の線維化関連タンパク質の発現プロセスを抑制し、肺、腎臓、肝臓、心臓、皮膚、骨髄、膵臓、眼等の多様な組織での線維症の治療と予防、特に特発性肺線維症の治療、予防へ用いることができる。【選択図】図1
